This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Livagen (20 mg Vial)
Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator studied for its effects on peptidase inhibition and epigenetic modulation in aging tissues[1][4]. Preclinical research demonstrates Livagen strongly inhibits enkephalin-degrading enzymes[1] and induces heterochromatin decondensation with gene reactivation in aged cells[4]. No standardized human dosing exists.
Quick Reference
What is Livagen?
Research overview based on the cited scientific literature.
• Goal: Support cellular homeostasis and regenerative processes in aging tissues[3].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Livagen studied?
Livagen’s mechanisms involve peptidase inhibition and epigenetic modulation. The peptide strongly inhibits enkephalin-degrading enzymes (IC50 ≈ 20 μM) in human serum[1], which may prolong endogenous enkephalin activity. Notably, this occurs without direct opioid receptor binding[1]. In aging cells, Livagen has been shown to induce heterochromatin decondensation and reactivate ribosomal genes[4]. Preclinical studies in rat liver organ cultures demonstrated enhanced cellular structure and regenerative processes[3], while oral administration in aged rats shifted digestive enzyme activities toward youthful patterns[2].
What does the research report about Livagen?
Observations from preclinical and in vitro literature.
• Supports inhibition of enkephalin-degrading enzymes, potentially prolonging endogenous enkephalin signaling[1].
• May modulate gene expression and chromatin structure in aging tissues[4].
• Preclinical evidence suggests support for cellular homeostasis and regenerative capacity[3].
• In aged rodents, oral dosing normalized digestive enzyme activity toward youthful levels[2].
• No human clinical administration studies have been reported; side effect profile in humans is unknown.
• Occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.
Research Limitations / Risk Notes
No standardized human dosing exists for Livagen, and no human clinical administration studies have been reported. The dosing approach described here is extrapolated from preclinical data and similar peptide bioregulators. The supplied evidence includes in vitro human-serum research, rat studies, organotypic liver cultures, and aging-cell research, so these findings should not be treated as established human clinical outcomes.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
